Chris Ryan

Chris Ryan joined OncLive in November 2021 as a senior editor and became the website's managing editor in October 2023. Before arriving at MJH Life Sciences, he spent nearly a decade covering professional and high school sports—including the New Jersey Devils and the NHL from 2016 to 2021—for The Star-Ledger and NJ.com. Email: chryan@onclive.com

Articles

Invikafusp Alfa Demonstrates Single-Agent Activity in PD-(L)1–Resistant Solid Tumors

November 11th 2024

Phase 1 data showed the potential for invikafusp alfa as a precision cancer immunotherapeutic agent in solid tumors after exposure to PD-(L)1 therapy.

Sylvester Annual Oncology Update Highlights Different Perspectives in Bladder Cancer, Other Treatment Areas

November 10th 2024

Janaki Neela Sharma, MD, discusses takeaways from the Sylvester Comprehensive Cancer Center 2024 Annual Oncology Update.

Post Hoc Analysis Reveals Potential Serum Glycoproteomic Biomarkers for Nivolumab/Cabozantinib in Advanced RCC

November 9th 2024

David A. Braun, MD, PhD, discusses the potential for protein glycosylation as a biomarker to predict nivolumab/cabozantinib responses in advanced RCC.

FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

November 8th 2024

The FDA has approved obecabtagene autoleucel for relapsed/ refractory B-cell precursor acute lymphoblastic leukemia.

FDA Approval Sought for Sunvozertinib in Pretreated EGFR Exon 20+ Advanced NSCLC

November 8th 2024

A new drug application has been submitted to the FDA for sunvozertinib in pretreated EGFR exon 20–positive advanced non–small cell lung cancer.

FDA, EMA Receive Applications for Subcutaneous Daratumumab in High-Risk Smoldering Myeloma

November 8th 2024

Applications have been submitted to the FDA and EMA seeking approval for daratumumab in high-risk smoldering multiple myeloma.

Immune Profile Score Algorithmic Test Is Now Available to Help Inform Checkpoint Inhibitor Use in Cancer

November 7th 2024

The Immune Profile Score algorithmic test is now available for clinical use as a prognostic tool for immune checkpoint inhibitors in solid tumors.

DK210 (EGFR) Induces Immune Response Without Increased CRS or Regulatory T Cells in Solid Tumors

November 7th 2024

DK210 (EGFR) showed evidence of wild-type IL-2 signaling, CRS mitigation, and immune response signaling in patients with solid tumors.

Siglec-15 Represents Potential Therapeutic Target in NSCLC, Other Solid Tumors

November 7th 2024

Siglec-15 was expressed in tumor cells and tumor-associated macrophages in tissue samples from non–small cell lung cancer and other solid tumors.

Enfortumab Vedotin Plus Pembrolizumab Leads to Shifts in Frontline Metastatic Urothelial Cancer Management

November 7th 2024

Janaki Neela Sharma, MD, discusses the road to FDA approval for enfortumab vedotin plus pembrolizumab in locally advanced or metastatic urothelial cancer.

Review Key Genitourinary Cancer Data From the 2024 ESMO Congress With Chandler Park, MD

November 6th 2024

Chandler Park, MD, talks through key updates in genitourinary cancer research from the 2024 ESMO Congress.

Zongertinib Research Could Represent Next Wave in HER2-Mutated NSCLC Management

November 6th 2024

Christina S. Baik, MD, MS, discusses the types of HER2 testing that should be performed in NSCLC and the design of the phase 3 Beamion LUNG-2 trial.

NICE Advocates Reimbursement for Avapritinib in Aggressive Systemic Mastocytosis, Other Hematologic Malignancies

November 6th 2024

NICE issued a final guidance recommending reimbursement of avapritinib monotherapy in adult patients with ASM, SM-AHN, or mast cell leukemia.

Indirect Comparison Shows Comparable Efficacy, Improved Safety for Acalabrutinib vs Ibrutinib in R/R Mantle Cell Lymphomal Lymphoma

November 5th 2024

An indirect comparison did not show significant differences in survival for acalabrutinib vs ibrutinib in relapsed/refractory mantle cell lymphoma.

Preoperative Radiotherapy Plus Perioperative Chemo Improves pCR Rate but Not Survival in Resectable Gastric/GEJ Cancer

November 5th 2024

Trevor Leong, MBBS, MD, FRANZCR, discusses findings from the TOPGEAR trial assessing perioperative chemoradiotherapy in gastric/GEJ cancer.

(Z)-endoxifen Reduces MBD, Is Well Tolerated in Premenopausal Women Screened for Breast Cancer

November 5th 2024

(Z)-endoxifen significantly reduced mammographic breast density and was generally well tolerated in premenopausal women screened for breast cancer.

FDA Extends PDUFA Date for Zenocutuzumab in NRG1+ NSCLC and Pancreatic Cancer

November 5th 2024

The FDA has extended the PDUFA date of the BLA for zenocutuzumab in NRG1-positive non–small cell lung cancer and pancreatic cancer.

How to Use Toripalimab Plus Chemotherapy in Nasophryngeal Carcinoma: With Tarek Mekhail, MD, MSC, FRCSI, FRCSEd

November 4th 2024

Dr Mekhail discusses the rationale for combining chemotherapy with the PD-1 inhibitor toripalimab in patients with nasopharyngeal carcinoma.

Regorafenib Provides Modest Survival Benefit in Refractory Advanced Gastric/GEJ Cancer

November 4th 2024

Regorafenib improved overall survival vs placebo in refractory advanced gastric or gastroesophageal junction cancer.

Continued Development of RAS Inhibitors Leads the Charge in Pancreatic Cancer Research

November 4th 2024

Tanios S. Bekaii-Saab, MD, discusses the evolving role of RAS-targeted therapies in pancreatic cancer and where future research in the field may be headed.